candesartan has been researched along with Kidney Failure, Chronic in 23 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we examined the effects of the ANG II receptor type 1 (AT1R) blockade using candesartan on long-term renal molecular and functional changes in response to partial unilateral ureteral obstruction (PUUO)." | 7.74 | Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. ( Djurhuus, JC; Frøkiaer, J; Jørgensen, TM; Knepper, M; Nielsen, S; Nørregaard, R; Pedersen, M; Topcu, SO; Wang, G, 2007) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 5.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| " Here, we examined the effects of the ANG II receptor type 1 (AT1R) blockade using candesartan on long-term renal molecular and functional changes in response to partial unilateral ureteral obstruction (PUUO)." | 3.74 | Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. ( Djurhuus, JC; Frøkiaer, J; Jørgensen, TM; Knepper, M; Nielsen, S; Nørregaard, R; Pedersen, M; Topcu, SO; Wang, G, 2007) |
| "Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose." | 3.72 | Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. ( Fairley, KF; Kincaid-Smith, P; Packham, D, 2004) |
| "Rats with adenine-induced chronic renal failure (A-CRF) develop metabolic and cardiovascular abnormalities resembling those in patients with chronic kidney disease." | 1.39 | Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness. ( Carlström, M; Grimberg, E; Guron, G; Johansson, ME; Lundberg, JO; Lundgren, J; Nguy, L; Nilsson, H; Teerlink, T, 2013) |
| "In end-stage renal disease (ESRD) the incidence of genomic damage is increased." | 1.37 | AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment. ( Bahner, U; Grupp, C; Heidland, A; Klassen, A; Rutkowski, P; Schupp, N; Sebeková, K; Stopper, H, 2011) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 1.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguy, L | 1 |
| Johansson, ME | 1 |
| Grimberg, E | 1 |
| Lundgren, J | 1 |
| Teerlink, T | 1 |
| Carlström, M | 1 |
| Lundberg, JO | 1 |
| Nilsson, H | 1 |
| Guron, G | 1 |
| Cao, X | 1 |
| Nakamura, Y | 1 |
| Wada, T | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Suzuki, H | 2 |
| Kanno, Y | 2 |
| Sugahara, S | 1 |
| Ikeda, N | 1 |
| Shoda, J | 1 |
| Takenaka, T | 2 |
| Inoue, T | 1 |
| Araki, R | 1 |
| Shigenaga, A | 1 |
| Tamura, K | 1 |
| Dejima, T | 1 |
| Ozawa, M | 1 |
| Wakui, H | 1 |
| Masuda, S | 1 |
| Azuma, K | 1 |
| Tsurumi-Ikeya, Y | 1 |
| Mitsuhashi, H | 1 |
| Okano, Y | 1 |
| Kokuho, T | 1 |
| Sugano, T | 1 |
| Ishigami, T | 1 |
| Toya, Y | 1 |
| Uchino, K | 1 |
| Tokita, Y | 1 |
| Umemura, S | 1 |
| Schorn, R | 1 |
| Gaspert, A | 1 |
| Cohen, CD | 1 |
| Schupp, N | 1 |
| Rutkowski, P | 1 |
| Sebeková, K | 1 |
| Klassen, A | 1 |
| Bahner, U | 1 |
| Grupp, C | 1 |
| Heidland, A | 1 |
| Stopper, H | 1 |
| Marson, BP | 1 |
| Poli de Figueiredo, CE | 1 |
| Tanus-Santos, JE | 1 |
| Ueno, T | 1 |
| Kaname, S | 1 |
| Takaichi, K | 1 |
| Nagase, M | 1 |
| Tojo, A | 1 |
| Onozato, ML | 1 |
| Fujita, T | 1 |
| Matsuda, H | 1 |
| Hayashi, K | 1 |
| Homma, K | 1 |
| Yoshioka, K | 1 |
| Kanda, T | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Wakino, S | 1 |
| Saruta, T | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, KF | 1 |
| Packham, D | 1 |
| Phakdeekitcharoen, B | 1 |
| Leelasa-nguan, P | 1 |
| Kim, EJ | 1 |
| Jung, YW | 1 |
| Kwon, TH | 1 |
| Nakamura, T | 2 |
| Takahashi, A | 1 |
| Takase, H | 1 |
| Toriyama, T | 1 |
| Sugiura, T | 1 |
| Kurita, Y | 1 |
| Ueda, R | 1 |
| Dohi, Y | 1 |
| Furuya, R | 1 |
| Odamaki, M | 1 |
| Kumagai, H | 1 |
| Hishida, A | 1 |
| Topcu, SO | 1 |
| Pedersen, M | 1 |
| Nørregaard, R | 1 |
| Wang, G | 1 |
| Knepper, M | 1 |
| Djurhuus, JC | 1 |
| Nielsen, S | 1 |
| Jørgensen, TM | 1 |
| Frøkiaer, J | 1 |
| Almirall, J | 1 |
| Valenzuela, MP | 1 |
| Lopez, T | 1 |
| Yu, C | 1 |
| Gong, R | 1 |
| Rifai, A | 1 |
| Tolbert, EM | 1 |
| Dworkin, LD | 1 |
| García Donaire, JA | 1 |
| Ruilope, LM | 1 |
| Nishimura, M | 1 |
| Takahashi, H | 1 |
| Yoshimura, M | 1 |
| Obata, J | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yoshida, Y | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Shibasaki, Y | 1 |
| Mori, Y | 1 |
| Tsutumi, Y | 1 |
| Masaki, H | 1 |
| Sakamoto, K | 1 |
| Murasawa, S | 1 |
| Maruyama, K | 1 |
| Moriguchi, Y | 1 |
| Tanaka, Y | 1 |
| Iwasaka, T | 1 |
| Inada, M | 1 |
| Matsubara, H | 1 |
| Taal, MW | 1 |
| Chertow, GM | 1 |
| Rennke, HG | 1 |
| Gurnani, A | 1 |
| Jiang, T | 1 |
| Shahsafaei, A | 1 |
| Troy, JL | 1 |
| Brenner, BM | 1 |
| Mackenzie, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00530595] | 0 participants | Interventional | Completed | ||||
| Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Doxycycline; Humans; K | 2012 |
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinica | 2007 |
6 trials available for candesartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphen | 2009 |
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2004 |
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2005 |
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2006 |
15 other studies available for candesartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness.
Topics: Adenine; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Benzimidazoles; | 2013 |
L/N-type Ca
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2017 |
[Anti-RNA polymerase III antibodies in scleroderma renal crisis].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2010 |
AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2011 |
LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2004 |
Angiotensin II AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Aquaporins; Benzimidazoles; Biphenyl | 2005 |
Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Bipheny | 2006 |
Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aquaporin 2; Benzim | 2007 |
Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2007 |
Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Upregulation of the brain renin-angiotensin system in rats with chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidaz | 1999 |
Mechanisms underlying renoprotection during renin-angiotensin system blockade.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Chemokine CCL2 | 2001 |